BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, June 18, 2026
Breaking News: Viva in vivo! At EHA, in vivo CAR T data continues to impressBreaking News: Ongoing coverage of the Ebola outbreak
Home » Topics » BioWorld Asia

BioWorld Asia
BioWorld Asia RSS Feed RSS

South Korean shield, coronavirus

Novavax’s protein-based COVID-19 vaccine wins approval in South Korea

Jan. 18, 2022
By Gina Lee

South Korea’s Ministry of Food and Drug Safety (MFDS) has greenlighted Novavax Inc.’s Nuvaxovid, making it the first protein-based COVID-19 vaccine to be approved for commercial use in the country. The regulatory win for Novavax adds to emergency use authorizations (EUA) for the product, also known as NVX-CoV2373, in India, Indonesia and the Philippines, as well as an emergency use listing from the World Health Organization. On Jan. 12, the company said it expects to submit an EUA request to the FDA after one month.


Read More
Parkinson's disease illustration showing neurons containing alpha-synuclein

Sanofi in-licenses ABL Bio Parkinson’s drug for $1B as alpha-synuclein research heats up

Jan. 18, 2022
By Richard Staines
Targeting the toxic alpha-synuclein protein found in the brains of people with Parkinson’s is one of the most promising approaches to treat the disease in the clinic – but getting any drug into the brain is a challenge. Sanofi SA has joined with ABL Bio Inc. to solve this problem, in-licensing ABL-301, a preclinical bispecific antibody that locks on to misfolded alpha-synuclein but also includes a molecular “shuttle” that allows it to penetrate the blood-brain barrier.
Read More
Eye and DNA

Cellusion raises $9.5M to support ocular cell therapy

Jan. 18, 2022
By Gina Lee
Cellusion Inc. recently closed a ¥1.1 billion ($9.5 million) financing, bringing its total 2021 fundraising to ¥1.7 billion. The company is preparing to enter the clinic with CL-S001, its corneal endothelial substitute cell candidate for treating corneal edema due to endothelial dysfunction, or bullous keratopathy.
Read More
Pills spilling out of prescription bottle

Everest acquires rights to 3CL protease inhibitors to develop antivirals for COVID-19

Jan. 18, 2022
By David Ho
Shanghai-based Everest Medicines Ltd. has won exclusive global rights to a set of viral 3C-like (3CL) protease inhibitors from Singapore's national drug discovery platform, the Experimental Drug Development Centre (EDDC), in a deal worth up to $214.5 million.
Read More
Vial and three syringes

Cansino receives NMPA’s first approval for quadrivalent meningococcal conjugate vaccine

Jan. 18, 2022
By Doris Yu
Cansino Biologics Inc. has received marketing approval from the NMPA for its ACYW-135 meningococcal conjugate vaccine, Menhycia, making it the first of its kind to be authorized in China. The approval marks “an important step in accelerating the development of China’s meningococcal vaccine immunization strategy,” the company said.
Read More

In the clinic for Jan. 11-17, 2022

Jan. 18, 2022
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Alar, Ascletis, Bharat Biotech International, Cansino, Cara, Hutchmed, I-Mab, Lianbio, Maruishi, Molecular Partners, Novartis, Ocugen, Pharmamar, Quantum Leap Healthcare Collaborative, Redhill, Zai Lab.
Read More

Other news to note for Jan. 18, 2022

Jan. 18, 2022
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Accuredit, Adagio, Bharat Biotech International, Bold, Curateq Biologics, Glaxosmithkline, Iaso, Immune Biosolutions, Innovent, Insilico Medicine Hong Kong, N1 Life, Neocura Bio Medical Technology, Neurorx, Ocugen, Orion, Phoremost, Relief, Revelation, Sana, Shanghai Fosun, Vir.
Read More

Financings for Jan. 18, 2022

Jan. 18, 2022
Biopharmas in Asia-Pacific raising money in public or private financings: Celsion, Claritas, Geovax Labs, Pfizer, Postera.
Read More

Regulatory actions for Jan. 11-17, 2022

Jan. 18, 2022
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Adamis, Ascletis, Basilea, Biocon, Cansino, Carsgen, Edesa, Glaxosmithkline, Hutchmed, Imcyse, Immunome, Innovent, Jeil, Laekna Therapeutics Shanghai, Mitsubishi Tanabe Pharma America, Novavax, Pfizer, Rockwell Medical, SK, Viatris, Vir.
Read More
Australia map, flag

Australia gears up for clinical trials with psychedelics to treat mental health disorders

Jan. 18, 2022
By Tamra Sami
PERTH, Australia – Australia has recently established new research and discovery centers to study psychedelic treatments for mental health disorders.
Read More
Previous 1 2 … 297 298 299 300 301 302 303 304 305 … 1489 1490 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing